A novel t(15;17) translocation in acute myeloid leukaemia not associated with PML/RARalpha rearrangement.
We report a novel t(15;17)(q15;q11) translocation in acute myeloid leukaemia (AML M4) which was not associated with PML/RARalpha rearrangement or with acute promyelocytic leukaemia (APL) morphology. The leukaemia behaved in refractory fashion, with 70% blasts in the bone marrow after the first course of chemotherapy. In view of the refractory behaviour of the leukaemia, the patient was treated with high dose chemotherapy and autologous stem cell rescue. The patient is alive and well 22 months post-autologous stem cell transplant. This case demonstrates that while cytogenetic analysis provides important diagnostic and prognostic information, the precise location of the chromosomal breakpoints is critical in the interpretation of cytogenetic results.
Cotter
M
M
Department of Haematology, Adelaide and Meath Hospital, Incorporating the National Children's Hospital, Dublin, Ireland. melanie.cotter@amnch.ie
Enright
H
H
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D019457:Chromosome Breakage; D002884:Chromosomes, Human, Pair 15 / Q000235:genetics / Q000648:ultrastructure*; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics / Q000648:ultrastructure*; D050676:Core Binding Factor Alpha 2 Subunit; D003561:Cytarabine / Q000008:administration & dosage; D004268:DNA-Binding Proteins / Q000235:genetics; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D015479:Leukemia, Myelomonocytic, Acute / Q000235:genetics*; D036102:Peripheral Blood Stem Cell Transplantation; D011518:Proto-Oncogene Proteins / Q000235:genetics; D012074:Remission Induction; D016879:Salvage Therapy; D013866:Thioguanine / Q000008:administration & dosage; D014157:Transcription Factors / Q000235:genetics; D014178:Translocation, Genetic; D014182:Transplantation, Autologous; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*
D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins; D011518:Proto-Oncogene Proteins; C493728:RUNX1 protein, human; D014157:Transcription Factors; D003561:Cytarabine; D014740:Vidarabine; D013866:Thioguanine; C024352:fludarabine; D003630:Daunorubicin